U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C38H64O49S7
Molecular Weight 1529.34
Optical Activity UNSPECIFIED
Defined Stereocenters 25 / 25
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IDRAPARINUX

SMILES

[H][C@]5(O[C@H]1[C@H](OC)[C@@H](OC)[C@]([H])(O[C@@H]2[C@@H](COS(O)(=O)=O)O[C@]([H])(O[C@H]3[C@H](OC)[C@@H](OC)[C@]([H])(O[C@@H]4[C@@H](COS(O)(=O)=O)O[C@H](OC)[C@H](OS(O)(=O)=O)[C@H]4OS(O)(=O)=O)O[C@H]3C(O)=O)[C@H](OS(O)(=O)=O)[C@H]2OS(O)(=O)=O)O[C@@H]1C(O)=O)O[C@H](COS(O)(=O)=O)[C@@H](OC)[C@H](OC)[C@H]5OC

InChI

InChIKey=AJBMORBNKXNZSF-COSHMZDQSA-N
InChI=1S/C38H64O49S7/c1-64-15-12(9-72-88(43,44)45)76-35(27(68-5)18(15)65-2)80-21-19(66-3)28(69-6)37(82-25(21)32(39)40)79-17-14(11-74-90(49,50)51)77-38(31(87-94(61,62)63)24(17)85-92(55,56)57)81-22-20(67-4)29(70-7)36(83-26(22)33(41)42)78-16-13(10-73-89(46,47)48)75-34(71-8)30(86-93(58,59)60)23(16)84-91(52,53)54/h12-31,34-38H,9-11H2,1-8H3,(H,39,40)(H,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)(H,55,56,57)(H,58,59,60)(H,61,62,63)/t12-,13-,14-,15-,16-,17-,18+,19+,20+,21+,22+,23+,24+,25+,26-,27-,28-,29-,30-,31-,34+,35-,36-,37-,38-/m1/s1

HIDE SMILES / InChI
Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events. However, clinical trials have revealed that idraparinux had lead to bleeding. As a result, Sanofi stopped the development of the drug.

Approval Year

PubMed

PubMed

TitleDatePubMed
Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.
2008 Jan 26
Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders.
2008 May
Idraparinux and idrabiotaparinux.
2010 Jan

Sample Use Guides

The administration of idraparinux in subcutaneous fixed doses of 2.5 mg once weekly was found to be as effective and safe as conventional antithrombotic therapy in the initial treatment of patients with deep vein thrombosis, but less effective than standard therapy in the initial treatment of patients with primary pulmonary embolism
Route of Administration: Other
Name Type Language
IDRAPARINUX
MI   WHO-DD  
Common Name English
SR34006
Code English
SR-34006
Code English
IDRAPARINUX [MI]
Common Name English
Idraparinux [WHO-DD]
Common Name English
Code System Code Type Description
WIKIPEDIA
IDRAPARINUX
Created by admin on Fri Dec 15 21:31:57 GMT 2023 , Edited by admin on Fri Dec 15 21:31:57 GMT 2023
PRIMARY
SMS_ID
100000092150
Created by admin on Fri Dec 15 21:31:57 GMT 2023 , Edited by admin on Fri Dec 15 21:31:57 GMT 2023
PRIMARY
FDA UNII
6ADD3H8MFZ
Created by admin on Fri Dec 15 21:31:57 GMT 2023 , Edited by admin on Fri Dec 15 21:31:57 GMT 2023
PRIMARY
CAS
162610-17-5
Created by admin on Fri Dec 15 21:31:57 GMT 2023 , Edited by admin on Fri Dec 15 21:31:57 GMT 2023
PRIMARY
MESH
C479958
Created by admin on Fri Dec 15 21:31:57 GMT 2023 , Edited by admin on Fri Dec 15 21:31:57 GMT 2023
PRIMARY
EPA CompTox
DTXSID801027578
Created by admin on Fri Dec 15 21:31:57 GMT 2023 , Edited by admin on Fri Dec 15 21:31:57 GMT 2023
PRIMARY
DRUG BANK
DB06406
Created by admin on Fri Dec 15 21:31:57 GMT 2023 , Edited by admin on Fri Dec 15 21:31:57 GMT 2023
PRIMARY
PUBCHEM
3083445
Created by admin on Fri Dec 15 21:31:57 GMT 2023 , Edited by admin on Fri Dec 15 21:31:57 GMT 2023
PRIMARY
EVMPD
SUB25476
Created by admin on Fri Dec 15 21:31:57 GMT 2023 , Edited by admin on Fri Dec 15 21:31:57 GMT 2023
PRIMARY
MERCK INDEX
m6202
Created by admin on Fri Dec 15 21:31:57 GMT 2023 , Edited by admin on Fri Dec 15 21:31:57 GMT 2023
PRIMARY Merck Index